These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21859882)

  • 41. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
    Breman JG; Alilio MS; Mills A
    Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):1-15. PubMed ID: 15331814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural products drug discovery: accelerating the clinical candidate development using reverse pharmacology approaches.
    Patwardhan B; Vaidya AD
    Indian J Exp Biol; 2010 Mar; 48(3):220-7. PubMed ID: 21046974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patent holdings of US biotherapeutic companies in major markets.
    Sebastian TE; Yerram CB; Saberwal G
    Drug Discov Today; 2009 May; 14(9-10):442-5. PubMed ID: 19429502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Best practices for veterinary toxicologic clinical pathology, with emphasis on the pharmaceutical and biotechnology industries.
    Tomlinson L; Boone LI; Ramaiah L; Penraat KA; von Beust BR; Ameri M; Poitout-Belissent FM; Weingand K; Workman HC; Aulbach AD; Meyer DJ; Brown DE; MacNeill AL; Bolliger AP; Bounous DI
    Vet Clin Pathol; 2013 Sep; 42(3):252-69. PubMed ID: 23889060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patenting bioactive molecules from biodiversity: the Brazilian experience.
    Nogueira RC; de Cerqueira HF; Soares MB
    Expert Opin Ther Pat; 2010 Feb; 20(2):145-57. PubMed ID: 20099999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
    Grabowski HG; Moe JL
    Cancer Prev Res (Phila); 2008 Jul; 1(2):84-90. PubMed ID: 19138940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quinacrine sterilisations banned.
    Rao M
    Health Millions; 1998; 24(3):14. PubMed ID: 12293800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Institutional obstacles to expansion of world food production.
    Crosson PR
    Science; 1975 May; 188(4188):519-24. PubMed ID: 17740002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring opportunities for collaboration between the corporate sector and the dental education community.
    Alexander D; Clarkson J; Buchanan R; Chadwick G; Chesters R; Drisko CL; Douglass CW; Farrell L; Fletcher K; Makoni F; Monaco M; Nordquist B; Park NI; Riggs S; Schou L; Smales FC; Stamm JW; Toh CG; Volpe T; Ward P; Warren P
    Eur J Dent Educ; 2008 Feb; 12 Suppl 1():64-73. PubMed ID: 18289269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and population growth: the Indian experience.
    Chandna RC
    Popul Geogr; 1996; 18(1-2):9-26. PubMed ID: 12179067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical research opportunities: what you need to know for your practice.
    Glatz NF; Gregory SJ; Law BT; Riner RN
    Heart Dis; 2000; 2(4):287-92. PubMed ID: 11728271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 55. How can the postgraduate training program in pathology departments in India be improved?
    Bhusnurmath SR; Bhusnurmath BS
    Indian J Pathol Microbiol; 2011; 54(3):441-7. PubMed ID: 21934200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The challenges of immunogenicity in developing biosimilar products.
    Wadhwa M; Thorpe R
    IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioethics activities in India.
    Kumar NK
    East Mediterr Health J; 2006; 12 Suppl 1():S56-65. PubMed ID: 17037690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies.
    Bolon B; Barale-Thomas E; Bradley A; Ettlin RA; Franchi CA; George C; Giusti AM; Hall R; Jacobsen M; Konishi Y; Ledieu D; Morton D; Park JH; Scudamore CL; Tsuda H; Vijayasarathi SK; Wijnands MV
    Exp Toxicol Pathol; 2011 Jan; 63(1-2):187-95. PubMed ID: 20724123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.